- Home
- VERA
as 11-15-2024 4:00pm EST
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 2.5B | IPO Year: | 2021 |
| Target Price: | $54.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.28 - $51.61 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vera Therapeutics Inc. (VERA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SEIDENBERG BETH C | VERA | Director | Oct 28 '24 | Sell | $48.78 | 15,000 | $720,493.22 | 131,755 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Oct 9 '24 | Sell | $38.46 | 15,625 | $597,568.34 | 307,972 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Sep 25 '24 | Sell | $46.19 | 23,125 | $1,064,809.29 | 307,972 | |
| SEIDENBERG BETH C | VERA | Director | Sep 18 '24 | Sell | $42.11 | 16,476 | $696,233.08 | 131,755 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Sep 11 '24 | Sell | $37.54 | 15,625 | $585,934.07 | 307,972 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Aug 28 '24 | Sell | $37.17 | 30,320 | $1,117,139.78 | 307,972 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Aug 21 '24 | Sell | $39.76 | 14,471 | $575,424.84 | 307,972 |
Latest Vera Therapeutics Inc. News
VERA Breaking Stock News: Dive into VERA Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
6 days ago
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet
GlobeNewswire
6 days ago
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
GlobeNewswire
9 days ago
Vera Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewswire
9 days ago
Vera Therapeutics to Participate at Upcoming Investor Conferences
MT Newswires
9 days ago
Wedbush Raises Vera Therapeutics' Price Target to $38 From $30, Maintains Neutral rating
MT Newswires
10 days ago
Vera Therapeutics Shares Rise After Q3 Results
GlobeNewswire
10 days ago
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Compare VERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERA Vera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.